BioSpace News Archive

Expanded capabilities in company’s Immunogenicity and Immuno-oncology QSP Simulators broaden applicability for addressing safety and efficacy challenges

BioEquity Europe Digital Oxford Global’s Online Drug Discovery Week Jefferies Virtual Healthcare Conference 2021 Precision in Drug Discovery & Preclinical Virtual Summit European Hematology Association (EHA) 2021 Congress BIO International Convention 2021

Selecta Biosciences today reported financial results for the first quarter ended March 31, 2021 and provided a business update.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming virtual investor conferences: Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 11:35am ET Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:30pm ET

Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that it plans to release financial results for the first quarter ended March 31, 2021 after market close on Monday, May 17, 2021.

Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that in connection with the Company’s previously disclosed succession plan: Leonard Osser announced his intention to resign as Interim Chief Executive Officer

Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs, announced that it has filed its 2021 first quarter report. The Report shows that the Company had Cash & Cash Equivalents of $1,796,596 as of March 31, 2021, the period end.

Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced that an abstract highlighting positive data from the EQUATE study of itolizumab in acute graft-versus-host disease has been accepted for oral presentation at EHA2021 Virtual Congress.

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that management will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Wednesday, May 26.

DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, announced the appointment of Hongjun “Harry” Yang, Ph.D., former Executive Personalized Healthcare Strategy Leader at AstraZeneca, as Senior Vice President of Companion Diagnostics at DiaCarta.